Blockade of SUR1 receptors with glibenclamide has been involved in improved outcome in animal stroke models and investigational human studies by preventing brain swelling and enhancing neuroprotection.
Blocking SUR1 receptors using glibenclamide has been associated with better results in animal stroke models and preliminary human trials by reducing brain swelling and boosting neuroprotection.